Greenwich Lifesciences Announces Positive Immune Response Data From FLAMINGO-01 Phase III Clinical Trial
April 2 (Reuters) - Greenwich Lifesciences Inc GLSI.O:
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.